Year All20242023202220212020201920182017201620152014 Jun 04, 2024 Soleno Therapeutics Set to Join Russell 3000® Index May 22, 2024 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 May 22, 2024 Soleno Therapeutics to Participate in Upcoming Investor Conferences May 15, 2024 Soleno Therapeutics Stands with the Prader-Willi Syndrome Community May 09, 2024 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 02, 2024 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock May 02, 2024 Soleno Therapeutics Announces Proposed Public Offering of Common Stock Apr 30, 2024 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) Apr 19, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2024 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
May 09, 2024 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Apr 30, 2024 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)